Medicine
Aspruzyo Sprinkle 1000 mg granules
Aspruzyo Sprinkle 1000 mg granules is a prescription medicine containing Ranolazine for oral use, marketed by Sun Pharmaceutical Industries, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store ASPRUZYO Sprinkle at 20°C to 25°C (68°F to 77°F), excursions permitted…
Key facts
- Active ingredient (INN)
- Ranolazine
- Brand
- Aspruzyo Sprinkle
- Strength
- 1000 mg
- Dosage form
- Granules
- Route
- Oral
- Packs
- 1 granule, 30 granule, 60 granule
- Marketing authorisation holder
- Sun Pharmaceutical Industries
- Manufacturer
- Sun Pharmaceutical IndustriesIndia
- Origin register
- US FDA, United States
- Storage
- Store ASPRUZYO Sprinkle at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- C01EB18 Ranolazine
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 28 February 2022
- Identifiers
- RxCUI 2594753, 2594759, 2594760 +1DailyMed set ID dd9f81e4-50da-4551-aed5-559d304df42eNDC 47335-625Application NDA216018
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 granule in 1 packet | 47335-625-11 | Sun Pharmaceutical IndustriesIndia | 28 February 2022 |
| 30 granule in 1 carton | 47335-625-30 | Sun Pharmaceutical IndustriesIndia | 28 February 2022 |
| 60 granule in 1 carton | 47335-625-60 | Sun Pharmaceutical IndustriesIndia | 28 February 2022 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Ranolazine
Clinical summary
Ranolazine is an anti-anginal indicated for the treatment of chronic angina. It is available as extended-release tablets and granules for oral use. MedsAcross supplies Ranolazine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about RanolazineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- ASPRUZYO SPRINKLE prescribing information (Sun Pharmaceutical Industries) · U.S. National Library of Medicine, DailyMed
- Ranexa (previously Latixa): European public assessment report (EPAR) · European Medicines Agency
Need Aspruzyo Sprinkle 1000 mg granules for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.